PI3K/Akt/mTOR-IN-2

SKU: orb1689461

Description

PI3K/Akt/mTOR-IN-2 is a selective small molecule inhibitor of the PI3K/AKT/mTOR pathway with demonstrated in vitro anticancer activity. It exhibits potent, selective cytotoxicity against MDA-MB-231 breast cancer cells (IC50 = 2.29 µM) by inducing cell cycle arrest and apoptosis, making it a useful research tool for oncology and signal transduction studies.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 2757804-89-8
• MW: 285.29
• Purity: 99.61% (May vary between batches)
• Formula: C₁₇H₁₃F₂NO
• SMILES: Fc1cc(F)cc(c1)C1OCCc2c1[nH]c1ccccc21
• Target: PI3K,Akt,mTOR,Apoptosis
• Solubility: DMSO:55 mg/mL (192.79 mM)

Bioactivity

• Target IC50:
  PI3K/AKT/mTOR:2.29 μM
• In Vitro:
  PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 h) demonstrates significant anti-cancer efficacy, with IC50 values between 2.29 and 24.63 μM, notably 2.29 μM in MDA-MB-231 cells. It induces growth inhibition in MDA-MB-231 cells by causing cell cycle arrest at G0/G1 (1, 2, and 4 μM; 24 h), elicits dose- and time-dependent apoptosis (1, 2, and 4 μM; 24, 48, and 72 h), increases Bax expression and decreases Bcl-2 expression (1, 2, and 4 μM; 48 h), and triggers mitochondria-dependent apoptosis by disrupting mitochondrial membrane potential, increasing ROS, reducing GSH levels, and elevating intracellular Ca2+ (1, 2, and 4 μM; 24 h).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Apoptosis, Akt, mTOR, PI3K

Compound Identifiers

PubChem CID

163322396